7:03 AM
 | 
Mar 01, 2018
 |  BC Innovations  |  Translation in Brief

A path less traveled

How TNFα could be steered toward an antitumor signaling pathway

A team from PSL Research University has shown how a nitric oxide (NO)-donating compound steers TNFα signaling away from a pro-survival pathway towards one that promotes death in cancer cells. The findings suggest NO-donors could treat tumors that highly express TNFα, whether initially or in response to cytotoxic therapies.

Previous in vivo studies have demonstrated NO can enable tumors to overcome drug resistance to standard-of-care cytotoxic therapies, though its mechanism of action was unknown.

In a Cancer Research study published last month, a team from PSL’s École Pratique des Hautes Études (EPHE) published what it believes is the first evidence that NO exerts its antitumor effects by nitrosylating...

Read the full 522 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >